Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,392,918
  • Shares Outstanding, K 163,427
  • Annual Sales, $ 1,174 M
  • Annual Income, $ -48,170 K
  • 60-Month Beta 0.75
  • Price/Sales 3.70
  • Price/Cash Flow 36.06
  • Price/Book 4.04
Trade ALKS with:

Options Overview Details

View History
  • Implied Volatility 39.00% ( -7.12%)
  • Historical Volatility 51.61%
  • IV Percentile 19%
  • IV Rank 15.57%
  • IV High 93.24% on 03/04/22
  • IV Low 29.00% on 08/02/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 30
  • Volume Avg (30-Day) 245
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 21,412
  • Open Int (30-Day) 15,897

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.12
  • Number of Estimates 4
  • High Estimate -0.01
  • Low Estimate -0.20
  • Prior Year 0.13
  • Growth Rate Est. (year over year) -192.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.14 +10.67%
on 05/12/22
32.79 -11.77%
on 04/28/22
-0.43 (-1.46%)
since 04/14/22
3-Month
22.90 +26.33%
on 03/07/22
32.79 -11.77%
on 04/28/22
+2.14 (+7.99%)
since 02/16/22
52-Week
21.24 +36.21%
on 12/01/21
33.00 -12.33%
on 10/07/21
+6.67 (+29.96%)
since 05/14/21

Most Recent Stories

More News
CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

ALKS : 28.93 (+7.63%)
VRTX : 254.17 (+3.02%)
CRSP : 51.54 (-1.32%)
SESN : 0.4140 (-4.41%)
Medtronic's (MDT) Onyx Frontier DES Receives FDA Approval

Medtronic's (MDT) Onyx Frontier DES is utilized to treat patients with CAD.

UNH : 489.22 (+0.79%)
ALKS : 28.93 (+7.63%)
MDT : 103.81 (+1.11%)
MEDP : 140.00 (+0.34%)
Here's Why You Should Retain Charles River (CRL) Stock for Now

Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.

UNH : 489.22 (+0.79%)
ALKS : 28.93 (+7.63%)
CRL : 231.20 (-1.95%)
MEDP : 140.00 (+0.34%)
Will Repligen's (RGEN) COVID Woes Be Offset by Product Demand?

The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.

ALKS : 28.93 (+7.63%)
ANGN : 1.3000 (unch)
RGEN : 149.96 (-0.29%)
SESN : 0.4140 (-4.41%)
Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod

Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies....

NVO : 103.24 (-2.64%)
LLY : 299.38 (+2.66%)
ALKS : 28.93 (+7.63%)
SESN : 0.4140 (-4.41%)
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor

BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.

BMY : 76.91 (+1.46%)
AMGN : 243.87 (+0.19%)
ALKS : 28.93 (+7.63%)
BBIO : 6.74 (+1.81%)
NEOGEN (NEOG) Introduces InfiniSEEK for Cattle Breeders

NEOGEN's (NEOG) recent launch enables simultaneous low-pass whole genome sequencing and high-coverage genotyping at regions of interest.

UNH : 489.22 (+0.79%)
ALKS : 28.93 (+7.63%)
NEOG : 25.95 (-2.00%)
MEDP : 140.00 (+0.34%)
AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals

AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.

JNJ : 178.08 (+0.70%)
ALKS : 28.93 (+7.63%)
ABBV : 155.47 (+1.28%)
ABEO : 0.1800 (+11.18%)
Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Grow

Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.

UNH : 489.22 (+0.79%)
ALKS : 28.93 (+7.63%)
ALC : 70.97 (+0.45%)
MEDP : 140.00 (+0.34%)
STERIS (STE) Q4 Earnings Surpass Estimates, Gross Margin Rises

Robust performances across all four reporting segments drive STERIS' (STE) fiscal fourth-quarter revenues.

UNH : 489.22 (+0.79%)
ALKS : 28.93 (+7.63%)
STE : 217.94 (+0.81%)
MEDP : 140.00 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major...

See More

Key Turning Points

3rd Resistance Point 31.99
2nd Resistance Point 30.47
1st Resistance Point 29.70
Last Price 28.93
1st Support Level 27.42
2nd Support Level 25.90
3rd Support Level 25.13

See More

52-Week High 33.00
Last Price 28.93
Fibonacci 61.8% 28.51
Fibonacci 50% 27.12
Fibonacci 38.2% 25.73
52-Week Low 21.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar